NASDAQ:PROF

Profound Medical (PROF) Stock Price, News & Analysis

Profound Medical logo
$6.40 -0.19 (-2.87%)
Closing price 03:58 PM Eastern
Extended Trading
$6.42 +0.02 (+0.30%)
As of 04:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Profound Medical Stock (NASDAQ:PROF)

Advanced

Key Stats

Today's Range
$6.25
▼
$6.65
50-Day Range
$5.55
▼
$7.85
52-Week Range
$4.80
▼
$8.95
Volume
144,003 shs
Average Volume
170,034 shs
Market Capitalization
$234.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.50
Consensus Rating
Moderate Buy

Company Overview

Profound Medical Corp. is a Canadian medical-device company that develops MRI-guided therapies using focused ultrasound. Its systems combine magnetic resonance imaging with ultrasound energy to help clinicians target and treat tissue without conventional open surgery.

The company’s TULSA-PRO system is designed to ablate prostate tissue. It also offers Sonalleve, an MRI-guided focused-ultrasound platform developed for applications including the treatment of uterine fibroids and the palliation of pain from bone metastases.

Profound Medical serves healthcare providers in multiple international markets, using a mix of direct sales and distribution relationships. Its business focuses on developing and commercializing image-guided treatment systems and related services.

AI Generated. May Contain Errors.

Profound Medical Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
32nd Percentile Overall Score

PROF MarketRank™: 
1.586084098065 of 5 stars

Profound Medical scored higher than 32% of companies evaluated by MarketBeat, and ranked 720th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Profound Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 1 buy rating, no hold ratings, and 1 sell rating.

  • Upside Potential

    Profound Medical has a consensus price target of $11.50, representing about 78.6% upside from its current price of $6.44.

  • Amount of Analyst Coverage

    Profound Medical has only been the subject of 1 research reports in the past 90 days.

  • Read more about Profound Medical's stock forecast and price target.
  • Earnings Growth

    Earnings for Profound Medical are expected to grow in the coming year, from ($0.87) to ($0.46) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Profound Medical is -6.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Profound Medical is -6.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Profound Medical has a P/B Ratio of 5.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.39% of the float of Profound Medical has been sold short.
  • Short Interest Ratio / Days to Cover

    Profound Medical has a short interest ratio ("days to cover") of 9.83.
  • Change versus previous month

    Short interest in Profound Medical has recently increased by 1.45%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Profound Medical does not currently pay a dividend.

  • Dividend Growth

    Profound Medical does not have a long track record of dividend growth.

  • News Coverage This Week

    MarketBeat has tracked 1 news article for Profound Medical this week, compared to 2 articles on an average week.
  • Search Interest

    Only 1 people have searched for PROF on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Profound Medical insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    1.52% of the stock of Profound Medical is held by insiders.

  • Percentage Held by Institutions

    47.86% of the stock of Profound Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Profound Medical's insider trading history.
Receive PROF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Profound Medical and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PROF Stock News Headlines

Your father's savings lost half their value after 1971.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
Profound Medical (PRN) Gets a Buy from Stifel Nicolaus
Profound Medical (PROF) Q3 2026 Earnings Call Transcript
See More Headlines

PROF Stock Analysis - Frequently Asked Questions

Profound Medical's stock was trading at $7.87 at the start of the year. Since then, PROF stock has decreased by 18.2% and is now trading at $6.44.

Profound Medical (NASDAQ:PROF) released its quarterly earnings data on Thursday, November, 5th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.02. The company earned $9.83 million during the quarter, compared to the consensus estimate of $8.82 million. Profound Medical had a negative trailing twelve-month return on equity of 59.57% and a negative net margin of 137.51%.
Read the conference call transcript
.

Shares of PROF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Profound Medical investors own include Block (XYZ), Pfizer (PFE), ExxonMobil (XOM), Energy Transfer (ET), Ballard Power Systems (BLDP), Fulcrum Therapeutics (FULC) and Boeing (BA).

Company Calendar

Last Earnings
11/05/2026
Today
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:PROF
CIK
1628808
Employees
162
Year Founded
2008

Price Target and Rating

High Price Target
$12.00
Low Price Target
$11.00
Potential Upside/Downside
+79.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.93)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$42.57 million
Net Margins
-137.51%
Pretax Margin
-137.08%
Return on Equity
-59.57%
Return on Assets
-47.87%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.54
Quick Ratio
3.70

Sales & Book Value

Annual Sales
$16.10 million
Price / Sales
14.56
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.16 per share
Price / Book
5.52

Miscellaneous

Outstanding Shares
36,630,000
Free Float
36,070,000
Market Cap
$234.47 million
Optionable
Optionable
Beta
0.79

Social Links

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (NASDAQ:PROF) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners